research use only

Tideglusib GSK-3 inhibitor

Name: Tideglusib
SKU: S2823
Availability: InStock
Rating: 5 (29 reviews)

Cat.No.S2823

Tideglusib is an irreversible, non ATP-competitive GSK-3β inhibitor with IC50 of 60 nM in a cell-free assay; this compound fails to inhibit kinases with a Cys homologous to Cys-199 located in the active site. Phase 2.

Chemical Structure

Molecular Weight: 334.39

Jump to Mechanism of Action Cell Culture & Working Concentration Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.93%

99.93

Related Targets	PI3K Akt mTOR AMPK ATM/ATR DNA-PK PDPK1 PTEN PP2A PDK PI4K PIKfyve MELK
Related Products	CHIR-99021 (Laduviglusib) Laduviglusib (CHIR-99021) Hydrochloride SB216763 TWS119 CHIR-98014 BIO LY2090314 SB415286 AR-A014418 1-Azakenpaullone IM-12 CP21R7 TDZD-8 Indirubin (NSC 105327) AZD2858 AZD1080 BIO-acetoxime Bikinin GSK-3β Antibody [H1F15] GSK-3-α Antibody [G23H20] Phospho-GSK-3 (Ser21) Antibody [M22B5] GSK-3α Antibody [F10L17] Phospho-GSK-3α/β (Ser21/9) Antibody [M19M24] Paeoniae Radix Rubra Extract (E/Z)-GSK-3β inhibitor 1 PF-04802367 GSK-3β Antibody [B6C8] Phospho-GSK-3β (Ser9) Antibody [G6H5] GSK-3α/β Antibody [K1M18] Indirubin-3′-oxime

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
SH-SY5Y	Function assay	10 uM	1 hrs	Inhibition of GSK-3beta in human SH-SY5Y cells assessed as reduction in amyloid beta (25 to 35) -induced toxicity at 10 uM pre-incubated for 1 hrs before amyloid beta (25 to 35) addition and measured after 72 hrs post Abeta25-35 addition by MTT assay	29208522
SH-SY5Y	Function assay	30 uM	1 hrs	Inhibition of GSK-3beta in human SH-SY5Y cells assessed as reduction in amyloid beta (25 to 35) -induced toxicity at 30 uM pre-incubated for 1 hrs before amyloid beta (25 to 35) addition and measured after 72 hrs post Abeta25-35 addition by MTT assay	29208522
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight	334.39	Formula	C₁₉H₁₄N₂O₂S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	865854-05-3	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	NP031112, NP-12			Smiles	C1=CC=C(C=C1)CN2C(=O)N(SC2=O)C3=CC=CC4=CC=CC=C43

Solubility

In vitro
Batch:

DMSO : 1 mg/mL (2.99 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	4%DMSO 1 Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	2.500mg/ml (7.48mM)	Taking the 1 mL working solution as an example, add 40 μL of 62.5 mg/ml clear DMSO stock solution to 960 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.000mg/ml (2.99mM)	Taking the 1 mL working solution as an example, add 50 μL of 20 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.250mg/ml (3.74mM)	Taking the 1 mL working solution as an example, add 50 μL of 25 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	GSK-3β ^[1] (Cell-free assay) 60 nM
In vitro	Tideglusib irreversibly inhibits GSK-3, reduces tau phosphorylation, and prevents apoptotic death in human neuroblastoma cells and murineprimary neurons. ^[1] This compound (2.5 μM) inhibits glutamate-induced glial activation as evidenced by decreased TNF-α and COX-2 expression in rat primary astrocyte or microglial cultures. It (2.5 μM) also exerts a potent neuroprotective effect on cortical neurons from glutamate-induced excitotoxicity as evidenced by significant reduction in the number of Annexin-V-positive cells in rat primary astrocyte or microglial cultures. ^[2]
Kinase Assay	Binding Experiments with Radiolabeled Tideglusib
Kinase Assay	[³⁵S]Tideglusib (207 Bq/nmol) at 55 μM is incubated with 5 μM GSK-3β for 1 h at 25 °C in 315 μL of 50 mM Tris-HCl, pH 7.5, containing 150 mM NaCl and 0.1 mM EGTA. The incubation is extended for another 30 min after having added 35 μL of the same buffer with or without 100 mM DTE. Finally, a third 40-μL aliquot of each original sample is mixed with 10 μL of denaturing electrophoresis sample buffer without reducing agents, and 35 μL of this mixture is loaded onto a 10% polyacrylamide gel and subjected to SDS-PAGE, followed by fluorography of the dried gel.
In vivo	Tideglusib (50 mg/kg) injected into the adult male Wistar rats hippocampus dramatically reduces kainic acid-induced inflammation and has a neuroprotective effect in the damaged areas of the hippocampus. ^[2] This compound (200 mg/kg, oral) results in lower levels of tau phosphorylation, decreased amyloid deposition and plaque-associated astrocytic proliferation, protection of neurons in the entorhinal cortex and CA1 hippocampal subfield against cell death, and prevention of memory deficits in APP/tau double transgenic mice. ^[3]
References	[1] https://pubmed.ncbi.nlm.nih.gov/22102280/ [2] https://pubmed.ncbi.nlm.nih.gov/17522320/ [3] https://pubmed.ncbi.nlm.nih.gov/19523516/ [4] https://pubmed.ncbi.nlm.nih.gov/35514314/

Applications

Methods	Biomarkers	Images	PMID
Western blot	KDM1A / Nestin / OCT4 / CD133 / Tuj-1		27501329
Growth inhibition assay	Cell viability		27501329

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02586935	Completed	Autism Spectrum Disorders	Evdokia Anagnostou\|Holland Bloorview Kids Rehabilitation Hospital\|McMaster University\|University of Western Ontario Canada\|Unity Health Toronto\|University of Toronto\|Anagnostou Evdokia M.D.	February 10 2016	Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I want to deliver it via i.p. injection, can you suggest one?

Answer:
This compound can be dissolved in 4% DMSO+corn oil at 2.5 mg/ml clearly. This is the highest concentration, since its solubility in DMSO is pretty low.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):